Studies on the Pfizer Inc. drug Neurontin may have been skewed in order to have favorable results, reports Bloomberg. The drug is intended to treat epilepsy, however the studies focused on uses for Neurontin that had not yet been approved by the FDA. Researchers found that data from the studies on Neurontin that made its way into medical journals was inconsistent with the actual findings from the trials. Unfortunately, medical professionals assume these publications contain accurate information. What this points to is that Pfizer may have attempted to mislead the medical community about the effectiveness of Neurontin for certain off label uses. Pfizer denies this.
"Physicians are allowed to prescribe drugs for uses not approved by the FDA, and drugmakers are allowed to provide publications about off-label uses," the article states. When they are prescribing drugs for uses not approved by the FDA, studies such as the Neurontin study are doctors only source of information. Drugmakers need to provide accurate information in order to promote the best interests of doctors and patients. Our health depends on drugmakers’ reliability!
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.